. Author manuscript; available in PMC: 2020 Aug 15.

Published in final edited form as: J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):552–561. doi: 10.1097/QAI.0000000000002067

Table 8.

Differences in cascade outcomes across the three HIV clinics included in this study

Cascade step	TASO; n(row %)	Nagongera; n(row %)	Mulanda; n(row %)	P –value
Screened (n=456)	258 (56.6)	38 (8.3)	160 (35.1)	<0.0001^X
Diagnosed (n=218)	191 (87.6)	5 (2.3)	22 (10.1)	<0.0001^*
Initiated (n=192)	172 (89.6)	5 (2.6)	15 (7.8)	0.022^*
Retained (n=110)	105 (95.5)	1 (0.9)	4 (3.6)	0.007^*
Monitored (n=91)	89 (97.8)	1 (1.1)	1 (1.1)	0.016^*
Controlled (n=53)	52 (98.1)	0 (0.0)	1 (1.9)	0.619^*

Chi Square P-Value,

Fisher’s Exact P-value